Mass. court levies combined $13.6 million against AstraZeneca, Bristol-Myers Squibb

BOSTON A federal court in Massachusetts entered $12.9 million in damages against AstraZeneca and $695,594 against Bristol-Myers Squibb for the state’s class action members in a suit related to marketing the spread of certain drugs, according to law firms.

The judge, Patti B. Saris, found that AstraZeneca marketed the spread on its Zoladex drug, which is used to treat prostate cancer, selling it based on its profitability to doctors’ offices. She also found that less than 10 percent of Bristol-Myers Squibb’s sales were made within 5 percent of its list price, according to DowJones.

AstraZeneca and Bristol-Myers Squibb intend to appeal the ruling, which covers Massachusetts’s class-action participants.

Login or Register to post a comment.